Equifax Inc. (EFX)
Akero Therapeutics: Cirrhosis Reversal Data Derisks The Stock
Akero Therapeutics' EFX showed remarkable efficacy in reversing cirrhosis in the long-term SYMMETRY trial, a significant milestone in MASH treatment. EFX demonstrated consistent efficacy across different MASH stages, positioning it uniquely against competitors like Resmetirom, which only targets F2 and F3 MASH. Akero's financial health is strong, with a cash runway until 2028, bolstered by a recent $350 million upsized offering.
Bear Of The Day: Equifax (EFX)
Despite beating the number in each of the last four quarters, estimates have fallen along with the Zacks Rank for this stock.
4 Undervalued Growth Stocks to Buy and Hold for the Long Term
While most investors favor bull markets, bear markets offer unique opportunities to buy strong companies at lower prices. As the Nasdaq pulled back on Tuesday, analysts evaluated tech stocks for buying opportunities and identified potential long-term investments.
International Markets and Equifax (EFX): A Deep Dive for Investors
Evaluate Equifax's (EFX) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Equifax: Near-Term Weakness That May Lead To Guidance Revision (Rating Downgrade)
I am downgrading Equifax stock to a hold rating due to weak FY25 guidance, soft mortgage inquiry outlook, and hiring market pressures. Despite solid 4Q24 results and medium-term growth potential, the near-term earnings outlook is poor with decelerating revenue and EPS growth. Elevated mortgage rates and declining hiring volumes are significant headwinds, limiting EFX's ability to sustain recent growth rates.
Equifax Inc. (EFX) Q4 2024 Earnings Call Transcript
Equifax Inc. (NYSE:EFX ) Q4 2024 Earnings Conference Call February 6, 2025 8:30 AM ET Company Participants Trevor Burns - Senior Vice President, Head of Corporate Investor Relations Mark Begor - Chief Executive Officer John Gamble - Chief Financial Officer Conference Call Participants Jeff Muller - Baird Manav Patnaik - Barclays Andrew Steinerman - JPMorgan Toni Kaplan - Morgan Stanley Faiza Alwy - Deutsche Bank Kyle Peterson - Needham Craig Huber - Huber Research Partners Jason Haas - Wells Fargo Owen Lau - Oppenheimer Andrew Nicholas - William Blair Kelsey Zhu - Autonomous Research Scott Wurtzel - Wolfe Research Matt O'Neill - FT Partners Simon Clinch - Redburn Atlantic Arthur Truslove - Citi George Tong - Goldman Sachs Operator Greetings and welcome to the Equifax Corporate's Fourth Quarter 2024 Earning Conference Call. This time, all participants are in a listen-only mode.
Equifax Q4 Earnings Beat, Revenues Miss Despite Strong Segments
Robust growth across segments drives EFX's top line in the fourth quarter of 2024.
Weaker Hiring Market Creates Revenue Headwinds for Equifax
For Equifax, macro headwinds from a job market slowdown and the volatile mortgage market — where uneven loan demand has been a hallmark amid relatively high interest rates — have impacted top-line momentum and forward-looking guidance. As discussed during an earnings call with analysts Thursday (Feb.
Equifax (EFX) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Equifax (EFX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Equifax (EFX) Surpasses Q4 Earnings Estimates
Equifax (EFX) came out with quarterly earnings of $2.12 per share, beating the Zacks Consensus Estimate of $2.10 per share. This compares to earnings of $1.81 per share a year ago.
Equifax Gears Up to Report Q4 Earnings: What's in the Offing?
EFX's fourth-quarter 2024 revenues are expected to have increased due to healthy mortgage activities.
Ahead of Equifax (EFX) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Equifax (EFX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
